Showing 1 posts of 1 posts found.
The FDA has awarded MorphoSys and Incyte US approval for their Fc-modified cytolytic CD19-targeting monoclonal antibody Monjuvi (tafasitamab-cxix), when used …
Care Quality Commission appoints Emily Miles as Chief Executive
National survey aims to improve glaucoma care across the UK
Phase 3 trials support expanded use of Dysport for migraine prevention
Roche secures CE Mark for automated latent tuberculosis blood test
ReproNovo Phase 2 fertility study doses first participant